Damora Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses | ||
| Research and development | $6,398 | $23,770 |
| Acquired in-process research and development | 4,395 | — |
| General and administrative | 10,499 | 12,687 |
| Restructuring costs | 968 | 3,448 |
| Total operating expenses | 22,260 | 39,905 |
| Loss from operations | (22,260) | (39,905) |
| Other income (expense), net | ||
| Interest income, net | 844 | 1,689 |
| Foreign exchange transaction gain (loss), net | 18 | (197) |
| Gain on sale of equipment | — | 64 |
| Total other income, net | 862 | 1,556 |
| Loss before income tax expense | (21,398) | (38,349) |
| Income tax expense | (41) | — |
| Net loss | $(21,439) | $(38,349) |
| Net loss per common share, basic and diluted | $(18.53) | $(36.08) |
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 1,157,149 | 1,062,873 |
| Other comprehensive income (loss), net of tax | ||
| Currency translation gain (loss) | $(283) | $393 |
| Unrealized gain on marketable securities | — | 231 |
| Other comprehensive income (loss), net of tax | (283) | 624 |
| Total comprehensive loss | $(21,722) | $(37,725) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.